| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.0011 | 1 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | 0.0009 | 1 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.0013 | 1 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.00091 | 1 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | 0.00081 | 1 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | 0.001 | 1 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | -0.00096 | 1 |
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | 0.00045 | 1 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | 0.0011 | 1 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | 0.00057 | 1 |